Pharmaceutical In this week’s Expert View, Cem Zorlular, CEO of Er-Kim, argues that Europe’s W.A.I.T. indicator is becoming too blunt to capture how patients actually access medicines. He says the index risks deterring investment in markets where viable access routes already exist. 3 June 2026